Most preventive care does not save money in the strict sense. About 80% of preventive medical services that have been studied lead to higher overall healthcare spending, according to the Congressional Budget Office. That doesn’t mean prevention is a bad investment. It means the question is more complicated than a simple yes or no, and the answer depends heavily on which intervention you’re talking about, who receives it, and how you define “saving money.”
Why Most Prevention Costs More, Not Less
There’s an important distinction between “cost-saving” and “cost-effective.” A preventive measure is cost-saving when it reduces total spending while also improving health. It’s cost-effective when it improves health enough to justify the price, even if total spending goes up. Think of it this way: if a $50 screening prevents a $200,000 surgery in one out of every 500 people screened, the math might not favor savings. You spent $25,000 screening 500 people to avoid one $200,000 expense. But you still helped that one person avoid a catastrophic illness, and society generally considers that a reasonable trade.
A major analysis of published cost-effectiveness studies, reported in the New England Journal of Medicine, found that while some preventive measures do save money, the vast majority do not. This isn’t unique to prevention. Most medical treatments of any kind cost more than doing nothing. The question is whether the health gains justify the expense.
The Interventions That Actually Save Money
Childhood immunizations are the clearest win. Every $1 spent on routine childhood vaccines returns roughly $3.30 in direct healthcare savings and about $10.90 when you factor in broader benefits to society, like parents missing fewer days of work and children avoiding long-term disability. The CDC’s Vaccines for Children program, running since 1994, is one of the few large-scale preventive programs that genuinely costs less than the diseases it prevents.
Diabetes prevention is another area where the numbers work out favorably. For people with prediabetes, structured lifestyle programs (the kind that help with diet, exercise, and modest weight loss) have been shown to reduce medical costs by an average of $278 per person per quarter over three years in one Medicare study. A separate analysis of commercially insured adults estimated annual savings of $2,671 per participant for three years. A two-year study found an average reduction of $4,552 in total medical costs per person compared to non-participants. Digital versions of these programs appear to be outright cost-saving from a health system’s perspective over a 10-year window.
Certain cancer screenings also come out ahead. Colorectal cancer screening, for example, has produced negative cost-per-quality-adjusted-life-year figures in some studies, meaning the screening both improves health and reduces total costs. Catching colon cancer early, before it spreads, avoids the expensive chemotherapy, surgery, and hospital stays that late-stage treatment requires.
Cost-Effective but Not Cost-Saving
Many preventive interventions fall into a middle category: they cost more overall but deliver enough health benefit to be considered a good deal. In health economics, anything under roughly $50,000 to $100,000 per quality-adjusted life year is generally considered cost-effective, meaning society gets reasonable value for the money.
Cholesterol-lowering medication for people at elevated cardiovascular risk is a good example. Starting treatment at the commonly recommended risk threshold costs about $37,000 per quality-adjusted life year gained. That’s well within what’s considered a good value, and it prevents tens of thousands of heart attacks and strokes. But it doesn’t save money. Treating millions of people with daily medication for decades adds up, even when you subtract the cost of heart attacks that never happen.
Intensive blood pressure management tells a similar story. Bringing blood pressure down aggressively in adults over 50 costs roughly $28,000 to $47,000 per quality-adjusted life year gained, depending on how long the benefits last after treatment. Most analyses find this cost-effective, but total healthcare spending goes up because you’re adding medication, monitoring, and office visits for a large population to prevent events that would only have struck a fraction of them.
Why Screening Everyone Is Expensive
One of the core reasons prevention often costs more is the math of screening large, mostly healthy populations. When you screen 10,000 people to find the 50 who have early-stage disease, you’re paying for 10,000 tests, the follow-up appointments for hundreds of false positives, and the treatment for the 50 who genuinely benefit. The cost per person helped is enormous, even if the intervention works perfectly for those 50 individuals.
This plays out clearly in newer multi-cancer screening tests. When targeted at high-risk groups (people with genetic predispositions, heavy smoking histories, or certain pre-existing conditions), these tests can be highly cost-effective or even dominant, meaning they save money while improving outcomes. But when applied to the general population, the cost per quality-adjusted life year rises substantially, to around $66,000. The test works the same way in both groups. The difference is how many people you have to screen to find each case.
This creates a genuine tension in public health. Limiting screening to high-risk groups is more efficient, but it misses cancers that develop in people no one flagged as high-risk. Broader screening catches more cases but costs more per case caught.
The Long Game: How Costs Shift Over Time
Preventive care tends to cost more upfront before any savings appear. One study tracking personalized preventive care found that participants spent significantly more than non-participants in year one, with costs running about $86 higher per member per month. By year two, that gap had narrowed to about $29 per month. By year three, spending between the two groups was essentially identical, and 63% of participants were saving enough to cover their program fees.
This pattern matters for how we evaluate prevention. A three-year budget analysis might show prevention as a net cost, while a 10-year analysis of the same program might show it breaking even or saving money. Younger participants tended to take longer to see savings, reaching the break-even point around year three, while older participants with existing health conditions saw savings sooner through better management of those conditions.
There’s also a less intuitive wrinkle: people who stay healthier live longer, and living longer means more years of healthcare spending. A 55-year-old who avoids a fatal heart attack at 65 will go on to incur medical costs for another 15 or 20 years. Those additional years of life are genuinely valuable, but from a pure spending perspective, they don’t reduce lifetime costs. This is one reason the CBO concluded that expanded preventive care tends to increase overall healthcare spending even when it clearly improves health.
Workplace Wellness: Mixed Results
Employer-sponsored wellness programs are often marketed with impressive ROI figures, but the evidence is less clear-cut than the brochures suggest. One study of a long-term care company’s wellness program estimated a return of about $1.59 for every $1 invested, but the confidence interval was so wide (ranging from a loss of $35 to a gain of $14 per participant) that the result wasn’t statistically significant. The program may have saved money, or it may not have. The data simply couldn’t tell.
This is common in workplace wellness research. The programs that show the strongest returns tend to be the ones where participation is highest and the workforce has significant health risks to begin with. For a young, generally healthy workforce, the math is harder to make work.
What This Means in Practice
If you’re asking whether a specific preventive service, like a colonoscopy at 45, a flu shot, or a blood pressure check, is worth doing, the answer is almost certainly yes. The value of not getting colon cancer or not having a stroke is real, regardless of whether the aggregate math produces net savings for the healthcare system.
But if the question is whether a society can reduce its total healthcare bill by investing more in prevention, the honest answer is: probably not for most services. The CBO put it plainly: expanded government support for preventive care can improve people’s health, and for that reason it might be considered worthwhile even if it increased federal budget deficits. Prevention is, in most cases, a good use of money rather than a way to spend less money. The handful of exceptions, especially childhood vaccines and diabetes prevention programs, are genuinely cost-saving and deserve every dollar they get.